MLchartDataset catalogue

Rylaze

Term · Oncology and biomedicine · MLC-T-ONC-007525

A drug that is a recombinant form of asparaginase Erwinia chrysanthemi and is used with other drugs to treat adults and children aged 1 month or older with acute lymphoblastic leukemia or lymphoblastic lymphoma. It is used in people who cannot take the enzyme asparaginase that comes from the bacterium E. coli. Rylaze breaks down the amino acid asparagine and may stop the growth of cancer cells that need asparagine to grow. It may also kill cancer cells. Rylaze is a type of protein synthesis inhibitor.

Table 1. Record
IdentifierMLC-T-ONC-007525
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-007525",
  "term": "Rylaze",
  "field": "Oncology and biomedicine",
  "definition": "A drug that is a recombinant form of asparaginase Erwinia chrysanthemi and is used with other drugs to treat adults and children aged 1 month or older with acute lymphoblastic leukemia or lymphoblastic lymphoma. It is used in people who cannot take the enzyme asparaginase that comes from the bacterium E. coli. Rylaze breaks down the amino acid asparagine and may stop the growth of cancer cells that need asparagine to grow. It may also kill cancer cells. Rylaze is a type of protein synthesis inhibitor.",
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/rylaze/"
}

Record 14,626 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.